Best Practices For Interventional Cardiovascular Medical Device Trials In APAC

The Asia-Pacific region (APAC) is prepared to be key in addressing one of the word’s great health concerns. In our aging society, heart disease has become one of the most significant health problems worldwide. Its incidence is forecast to increase steadily as the number of people aged 60 and older is expected to double by 2025 and to triple by 2050. This aging will occur disproportionately in the Asia-Pacific region, which is predicted to account for half of the world’s cardiovascular disease burden by mid-century. This disease’s migration signals the need to anticipate and leverage the region’s role in therapeutic development and clinical trials.

The demographic shift and other factors point to the fast-growing region — which is expected to surpass the European Union in 2020 as the world’s second-largest med-tech market (after the United States) —becoming a major force in cardiovascular clinical trials.

Bringing interventional cardiac devices to market is a large and complex opportunity, and sponsors seeking to bring implantable cardiovascular products to the APAC market face significant challenges in designing and conducting clinical trials for stents, valves, pacemakers, ventricular assist devices and novel technologies.

In this webinar, the featured speakers will explore best practices for interventional cardiovascular medical device trials in APAC, considering:

  • Opportunities and challenges in clinical investigation of medical devices
  • The impact of a changing regulatory environment
  • Considerations in study conduct such as treatment protocols, data, endpoints and selection of principal investigators, sites and patients
  • Reimbursement strategies
  • Vendor selection